In France and in other countries, we observed a significant growth in human polyvalent immunoglobulins (PvIg) usage. PvIg is manufactured from plasma collected from numeral donors, and its production is complex. Supply tensions have been observed for several years, and it is necessary to limit their consumption. Therefore, French Health Authority (FHA) provided guidelines in June 2018 to restrict their usage. This research aims to assess the guidelines’ impact of the FHA on the use of PvIg. We analyzed data from Rennes University Hospital, where all PvIg prescriptions are reported electronically with quantity, rhythm, and indication. From the clinical data warehouses of RUH, we extracted comorbidities and lab results to evaluate the more complex guidelines. We globally noticed a reduction in the consumption of PvIg after the guidelines. Compliance with the recommended quantities and rhythms have also been observed. By combining two sources of data, we have been able to show an impact of FHA’s guidelines on the consumption of PvIg.